Patents by Inventor David D. Roberts
David D. Roberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8951527Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.Type: GrantFiled: August 5, 2009Date of Patent: February 10, 2015Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
-
Patent number: 8865672Abstract: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: GrantFiled: July 11, 2012Date of Patent: October 21, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts
-
Patent number: 8557788Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: GrantFiled: July 11, 2012Date of Patent: October 15, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey S. Isenberg, David D. Roberts
-
Patent number: 8344019Abstract: The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.Type: GrantFiled: February 13, 2012Date of Patent: January 1, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Michael L Pendrak, David D Roberts
-
Publication number: 20120295957Abstract: Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: ApplicationFiled: July 11, 2012Publication date: November 22, 2012Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Publication number: 20120295956Abstract: Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival.Type: ApplicationFiled: July 11, 2012Publication date: November 22, 2012Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Patent number: 8236313Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.Type: GrantFiled: October 5, 2007Date of Patent: August 7, 2012Assignees: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Washington UniversityInventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Publication number: 20120142751Abstract: The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.Type: ApplicationFiled: February 13, 2012Publication date: June 7, 2012Applicant: The United States of America, As Represented by The Secretary, Department ofInventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
-
Patent number: 8114406Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: GrantFiled: June 28, 2010Date of Patent: February 14, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David D. Roberts, Henry C. Krutzsch
-
Publication number: 20110135641Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.Type: ApplicationFiled: August 5, 2009Publication date: June 9, 2011Inventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
-
Publication number: 20110009311Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: ApplicationFiled: June 28, 2010Publication date: January 13, 2011Applicants: DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: DAVID D. ROBERTS, HENRY C. KRUTZSCH
-
Patent number: 7745144Abstract: The present invention relates to a peptide comprising the sequence R1—X1—X2—X3—X4—R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: GrantFiled: August 23, 2006Date of Patent: June 29, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David D. Roberts, Henry C. Krutzsch
-
Publication number: 20100112626Abstract: Method of diagnosing cancer in a mammal comprising assaying a test sample from the mammal for an increased level of semenogelin, wherein the increased level of semenogelin in the test sample is diagnostic for the cancer; methods of prognosticating and assessing the effectiveness of treatment of a cancer in a mammal based on the level of semenogelin in a test sample; a composition comprising (a) an immune-response inducing effective amount of (i) semenogelin or polypeptide fragment thereof or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii); a method of inducing an immune response to a cancer in a mammal comprising administering to the mammal the foregoing composition.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: David D. Roberts, Henry C. Krutzsch, Christine Krutzsch
-
Publication number: 20100092467Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.Type: ApplicationFiled: October 5, 2007Publication date: April 15, 2010Inventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Patent number: 7618789Abstract: Method of diagnosing cancer in a male mammal comprising obtaining and assaying a test sample for an increased level of semenogelin; method of diagnosing cancer in a female mammal comprising obtaining and assaying a test sample for the presence of semenogelin; methods of prognosticating and assessing the effectiveness of treatment of a cancer in a mammal comprising measuring the level of semenogelin in a test sample; method of inducing an immune response to a cancer in a mammal comprising administering to the mammal a composition comprising (a) an immune-response inducing effective amount of (i) semenogelin or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (ii); and composition comprising a carrier and (a) an immune-response inducing effective amount of (i) a polypeptide of any of SEQ ID NOS:1-27 or (ii) antibody thereto or (b) a recombinant vector encoding and expressing an immune-response inducing effective amount of (i) or (iiType: GrantFiled: April 3, 2002Date of Patent: November 17, 2009Assignee: The United States of America as represented by the Secretary of Department of Health and Human ServicesInventors: David D. Roberts, Henry C. Krutzsch, Christine Krutzsch, legal representative
-
Publication number: 20090203762Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.Type: ApplicationFiled: February 2, 2009Publication date: August 13, 2009Inventors: MICHAEL L. PENDRAK, DAVID D. ROBERTS
-
Patent number: 7504243Abstract: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.Type: GrantFiled: March 14, 2005Date of Patent: March 17, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael L. Pendrak, David D. Roberts
-
Publication number: 20080249026Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: ApplicationFiled: August 23, 2006Publication date: October 9, 2008Applicant: National Institutes of HealthInventors: David D. Roberts, Henry C. Krutzsch
-
Patent number: 7332167Abstract: Three hemoglobin-response genes in the pathogenic yeast Candida albicans are disclosed. The expression of these genes is specifically induced when the organism is exposed to hemoglobin during disseminated infections. The invention relates to the nucleic acid and amino acid sequences of these hemoglobin-response genes. The invention also relates to diagnostic methods, kits and compositions which employ the nucleic acid and amino acid sequences of the invention.Type: GrantFiled: February 18, 2005Date of Patent: February 19, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David D. Roberts, Sizhuang (Steve) Yan
-
Patent number: 7129052Abstract: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, and acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention.Type: GrantFiled: July 12, 2000Date of Patent: October 31, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David D. Roberts, Henry C. Krutzsch